The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial

Breast Cancer Research and Treatment
Noriko SagawaSeigo Kitano

Abstract

Chemotherapy-induced alopecia (CIA) is a distressing adverse effect of anticancer drugs; however, there are currently no mechanisms to completely prevent CIA. In this study, we performed a clinical trial to examine whether sodium N-(dihydrolipoyl)-l-histidinate zinc complex (DHL-HisZnNa), an alpha-lipoic acid derivative, prevents CIA in patients with breast cancer. Between July 2014 and May 2015, we performed a multi-center, single arm, clinical trial involving 103 breast cancer patients who received adjuvant chemotherapy at three medical institutions in Japan. During chemotherapy, a lotion containing 1% DHL-HisZnNa was applied daily to the patients' scalps. The primary endpoint was the incidence of grade 2 alopecia; the secondary endpoints were the duration of grade 2 alopecia, alopecia-related symptoms, and drug-related adverse events. Alopecia was evaluated by three independent reviewers using head photographs taken from four angles. Safety analysis was performed for 101 patients who started the protocol therapy. After excluding one patient who experienced disease progression during treatment, 100 patients who received at least two courses of chemotherapy underwent efficacy analysis. All original 101 patients developed grade...Continue Reading

References

Oct 2, 1986·The New England Journal of Medicine·M Martin-JimenezB Sangro
Oct 1, 1985·Scandinavian Journal of Clinical and Laboratory Investigation·J BülowM Hansen
Jul 1, 1996·Journal of the American Academy of Dermatology·M DuvicL D Compton
Oct 9, 1998·The Journal of Investigative Dermatology·M B SchilliA Menrad
Aug 5, 2003·The Journal of Investigative Dermatology. Symposium Proceedings·Vladimir A Botchkarev
Jun 19, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Floortje MolsWim P M Breed
Feb 19, 2009·The British Journal of Dermatology·C PrevezasP Reygagne
Dec 20, 2011·Journal of the American Academy of Dermatology·Susan Y ChonRashid M Rashid
Jun 16, 2012·Archives of Dermatological Research·Francesco D'AgostiniSilvio De Flora
Sep 26, 2013·Acta Oncologica·Corina J van den HurkJan W Coebergh
Jan 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J ChoS J Nam
Aug 2, 2014·International Journal of Cancer. Journal International Du Cancer·Hyoseung ShinSeung-Kwon Myung
Aug 6, 2014·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Wafaa Al-TameemiNikolaos T Georgopoulos
Feb 15, 2017·JAMA : the Journal of the American Medical Association·Julie NangiaMothaffar Rimawi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.